Answers are grounded in this paper and cite their sources.
Combination therapy improves response rates in KRAS-mutated low-grade serous ovarian cancer, suggesting a new standard of care.
Low-grade serous ovarian carcinoma (LGSOC) is a rare subtype of epithelial ovariancancer characterized by unique molecular features and poor response to conventionalchemotherapy. Recent advances in molecular profiling have led to the development oftargeted therapies, including MEK and FAK inhibitors. On May 8, 2025, the FDAapproved AVMAPKI™ FAKZYNJA™ CO-PACK, a combination of avutometinib anddefactinib, specifically for adults with KRAS-mutated recurrent LGSOC who haveundergone prior systemic therapy. This dual inhibitor regimen targets the MAPK andFAK signaling pathways, showing promising efficacy with an overall response rate of44% in clinical trials. While offering a novel and more effective treatment option, thetherapy requires careful monitoring for potential side effects such as liver toxicity andskin reactions. This approval marks a significant advancement in personalizedtreatment for LGSOC and highlights the need for improved accessibility to ensurepatient benefit.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: